explore -WSS

explore

author：entertainment 2025-09-30 21:22:22 - browse：291

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Pregnancy ages women, but effects reverse after delivery

focus

WSS

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Yancopoulos of Regeneron works to expand Dupixent success

Cancer, immunology, HIV research ensnared in fetal tissue politics

Asbestos ban is immediate, but health effects will linger for decades

FAMU bans football players from facility after release of rap video shot in team's locker room

leisure time

explore

entertainment

In Memoriam: Notable people who died in 2023

The response to Covid

Continuity nursing helped my family in our darkest PICU moments

Chinese researcher claims birth of first gene

Medical leaders decry Supreme Court decision on affirmative action

Medicare Advantage insurers pressure Biden for bigger payments

Medical records are filled with copy

Asbestos ban is immediate, but health effects will linger for decades

Activists slam private health insurers over coverage restrictions

Yancopoulos of Regeneron works to expand Dupixent success

focus

PrEP can help anyone prevent HIV. Why do so few people take it?

Texas board proposes rules on abortion law emergency exemption

'Patient friction coefficient' can gauge a clinical trial's patient burden

Medicare Advantage insurers pressure Biden for bigger payments

Pregnancy ages women, but effects reverse after delivery

Asbestos ban is immediate, but health effects will linger for decades

hotspot

hotspot

focus

leisure time